ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    nct 01966107
Previous Study | Return to List | Next Study

Evaluate the Effect of Aclidinium Bromide on Long-term Cardiovascular Safety and Exacerbations in Moderate to Very Severe COPD Patients. (ASCENT COPD)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01966107
Recruitment Status : Completed
First Posted : October 21, 2013
Results First Posted : December 6, 2018
Last Update Posted : December 6, 2018
Sponsor:
Information provided by (Responsible Party):
AstraZeneca

Brief Summary:
The Objectives of this study are to assess the safety of Aclidinium bromide on major adverse cardiovascular events (MACE), to assess the overall safety of Aclidinium bromide and to assess whether Aclidinium bromide reduces moderate or severe COPD exacerbations. This study is a double-blind, randomized, placebo controlled, parallel-group study to evaluate the effect of Aclidinium bromide on the cardiovascular safety and COPD exacerbations in patients with moderate to very severe COPD, as defined by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria.

Condition or disease Intervention/treatment Phase
COPD Chronic Obstructive Pulmonary Disease Moderate to Very Severe COPD Drug: Aclidinium Bromide Drug: Placebo Phase 4

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 3635 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Double-blind, Randomized, Placebo-controlled, Parallel-group, Phase IV Study to Evaluate the Effect of Aclidinium Bromide on Long-term Cardiovascular Safety and COPD Exacerbations in Patients With Moderate to Very Severe COPD (ASCENT COPD)
Actual Study Start Date : October 16, 2013
Actual Primary Completion Date : September 21, 2017
Actual Study Completion Date : September 21, 2017

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Aclidinium Bromide
Two-week washout/run-in period [for patients on a long-acting muscarinic antagonist (LAMA)] followed by a maximum of 36-month double-blind treatment period.
Drug: Aclidinium Bromide
400 μg, twice per day, oral administration via a multi-dose dry-powder inhaler (DPI)

Placebo Comparator: Placebo
Two-week washout/run-in period [for patients on a long-acting muscarinic antagonist (LAMA)] followed by a maximum of 36-month double-blind treatment period.
Drug: Placebo
Dose matched placebo, twice per day, oral administration via a multi-dose dry-powder inhaler (DPI)




Primary Outcome Measures :
  1. Rate of Moderate or Severe Chronic Obstructive Pulmonary Disease (COPD) Exacerbations Per Subject Per Year During the First Year of Treatment [ Time Frame: 12 months ]
    The rate (number of events per subject per year) of moderate or severe COPD exacerbations during the first year of treatment based on on-treatment analysis with treatment group, baseline inhaled corticosteroids (ICS) use, baseline COPD severity, history of at least 1 exacerbation in the past year, and smoking status as factors and the log of the exposure time adjusted for the time the subjects experienced exacerbations as an offset variable.

  2. Number of Participants With Major Adverse Cardiovascular Event (MACE) - on Study Analysis [ Time Frame: At Screening, Treatment period (upto 36 months) and Post-treatment follow-up (PTFU) ]
    To assess the cardiovascular (CV) safety of aclidinium bromide on MACEs. The number of subjects with an adjudicated composite MACE with treatment group, baseline CV severity, and smoking status as factors. MACE for the analyses was defined as any adjudicated event which was a composite of the total of CV death, non-fatal myocardial infarction (MI), or non-fatal stroke (on-study analysis).


Secondary Outcome Measures :
  1. Rate of Hospitalizations Due to COPD Exacerbation Per Subject Per Year During the First Year of Treatment- on Treatment Analysis [ Time Frame: 12 months ]
    To assess whether aclidinium bromide reduces moderate or severe COPD exacerbations. The rate of hospitalization (number of events per subject per year) due to COPD exacerbations during the first year of treatment based on on-treatment analysis with treatment group, baseline ICS use, baseline COPD severity, history of at least 1 exacerbation in the past year, and smoking status as factors and the log of the exposure time adjusted for the time the subjects experienced exacerbations as an offset variable.

  2. Number of Participants With Major Adverse Cardiovascular Event (MACE) or Other Serious Cardiovascular Events of Interest - On-study Analysis [ Time Frame: At Screening, Treatment period (upto 36 months) and Post-treatment follow-up (PTFU) ]

    To assess the CV safety of aclidinium bromide on MACEs. The number of subjects with an adjudicated MACE or other serious CV events of interest with treatment group, baseline CV severity, and smoking status as factors.

    Other serious CV events included events from Cardiac tachyarrhythmias plus preferred terms (PTs) Tachycardia, Heart rate increase, and Palpitation; Cardiac failure; Bradycardia and PTs Sinus arrest and Sinus bradycardia; Conduction defects; Conditions associated with Central nervous system haemorrhages and cerebrovascular accidents; and selected PTs included in the Other ischemic heart disease.




Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   40 Years to 130 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • 1. Male or female outpatients ≥ 40 years of age
  • 2. Current or former cigarette smokers with a smoking history of at least 10 pack-years
  • 3. A diagnosis of stable, moderate to very severe COPD (GOLD, 2015) with a post-bronchodilator FEV < 80% FEV1/forced vital capacity (FVC) ratio < 70%
  • 4. Must have at least one of the following 4 criteria:

    1. Documented cerebrovascular disease (stroke or transient ischemic attack, carotid stenosis)
    2. Documented coronary artery disease (angina, MI, angioplasty/stent/bypass)
    3. Documented peripheral vascular disease or history of claudication
    4. At least 2 of the following atherothrombotic risk factors as determined by the PI:

      1. Male ≥ 65 years or female ≥ 70 years
      2. Diabetes
      3. Dyslipidemia
      4. Hypertension
      5. Waist circumference inches males ≥ 40 in or in females ≥ 38 inches
      6. Evidence of renal dysfunction (eGFR < 60) and microalbuminuria (eGFR is based on modification of diet in renal disease [MDRD] equation, microalbuminuria is defined as ≥ 30-300 mcg/mg creatinine on a spot urine or ≥30 mg creatinine on a 24hr urine test)
  • 5. Maintained stable respiratory medications for 2 weeks prior to randomization (Appendix II)
  • 6. Able to perform pulmonary function test (PFT) maneuvers and follow study procedures
  • 7. Women of childbearing potential must have a negative serum β-human chorionic gonadotropin (HCG) pregnancy test at Visit 1A and be practicing medically acceptable method of contraception. Otherwise, female patients should be at least 1 year postmenopausal, surgically sterile (defined as having a hysterectomy or tubal ligation).
  • 8. Should understand study procedures and be willing to participate in the study as indicated by signing the ICF

Exclusion Criteria:

  • 1. Significant diseases other than COPD or cardiovascular disease (e.g., metastatic cancer) which, in the opinion of the PI, may either put the patient at risk because of participation in the study or a disease which may influence the results of the study or the patient's ability to participate in the study
  • 2. Unstable or life threatening cardiovascular disease or COPD as determined by the PI
  • 3. Patients with comorbid lung disease such as asthma, cystic fibrosis, bronchiectasis, interstitial lung disease, or pulmonary thromboembolic disease
  • 4. Planned lung transplant or lung volume reduction surgery
  • 5. Currently treated with a combination of LAMA and LABA/ICS therapy.
  • 6. Malignancy for which patient has undergone resection, radiation therapy or chemotherapy within 5 years prior to screening. Patients with treated basal cell and squamous cell (skin) carcinoma are allowed
  • 7. Respiratory infection or COPD exacerbation at Screening and/or within 4 weeks prior to screening
  • 8. Uncontrolled infection resulting from human immunodeficiency virus (HIV) and/or active hepatitis
  • 9. Reported history of drug or alcohol abuse within the past 12 months
  • 10. History of hypersensitivity reaction to inhaled anticholinergics, sympathomimetic amines, or inhaled medication or any component thereof (including report of paradoxical bronchospasm)
  • 11. History of acute urinary retention, treatment refractory benign prostatic hyperplasia (BPH), bladder neck obstruction, or narrow-angle glaucoma (Note: Patients with controlled, stable BPH are not excluded)
  • 12. Patients unable to use a multidose DPI or a pressurized metered-dose inhaler
  • 13. Treatment with any other investigational drug within 30 days (or 6 half-lives, whichever is longer) before Visit 1A
  • 14. Women who are pregnant or breastfeeding
  • 15. Use of any prohibited medication listed in Appendix II
  • 16. Employee or immediate relative of an employee of AstraZeneca, any of its affiliates or partners, or the study center

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01966107


  Show 468 Study Locations
Sponsors and Collaborators
AstraZeneca
Investigators
Principal Investigator: Kenneth R. Chapman, MD MSc FRCPC FACP FCCP GSK-CIHR Research Chair in Respiratory Health Care Delivery,
Principal Investigator: Robert Wise, MD Johns Hopkins Bayview Medical Center, Asthma and Allergy Center
  Study Documents (Full-Text)

Documents provided by AstraZeneca:
Study Protocol  [PDF] August 30, 2017
Statistical Analysis Plan  [PDF] October 23, 2017


Additional Information:
Responsible Party: AstraZeneca
ClinicalTrials.gov Identifier: NCT01966107     History of Changes
Other Study ID Numbers: D6560C00002
LAS-MD-45 ( Other Identifier: Forest Research )
First Posted: October 21, 2013    Key Record Dates
Results First Posted: December 6, 2018
Last Update Posted: December 6, 2018
Last Verified: November 2018

Additional relevant MeSH terms:
Lung Diseases
Lung Diseases, Obstructive
Pulmonary Disease, Chronic Obstructive
Respiratory Tract Diseases
Bromides
Muscarinic Antagonists
Anticonvulsants
Cholinergic Antagonists
Cholinergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs